Skip to content
Screener

BioCryst Pharmaceuticals BCRX Q1 2025 earnings

Reported May 5, 2025 · Before market open

Revenue$145.5MMiss by $4.2M
EPS$0.00Beat by $0.07
Revenue estimate$149.7M
EPS estimate-$0.07

Next report

Nov 2, 2026 (in a month)
Revenue estimate$165.7M
EPS estimate$0.10

Financials

Q1 2025

Income statement

See full
Revenue$145.5M+56.9%
Gross profit$141.0M+54.1%
Operating income$21.2M+247%
Net income$32.0K+100%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$106.9M+26.7%
Total debt$330.2M+1.9%
Total equity-$451.9M+5.1%
Total assets$480.0M+2.6%

Cash flow

See full
Operating cash flow-$27.5M+48.7%
CapEx$143.0K-39.1%
Free cash flow-$27.7M+48.7%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$1.57B+49.7%
Enterprise value$1.79B+39.1%
P/S3.1×+0.2×

Profitability

See full
Gross margin96.9%-1.7pp
Operating margin6.6%+3.7pp
Net margin-10.6%-4.8pp

Returns & leverage

See full
Current ratio2.9×-0.8×

Segments

By segment

See full
Reportable Segment$145.5M+56.9%

FAQ

When did BioCryst Pharmaceuticals report Q1 2025 earnings?
BioCryst Pharmaceuticals (BCRX) reported Q1 2025 earnings on May 5, 2025 before market open.
What were BioCryst Pharmaceuticals's Q1 2025 revenue and EPS?
BioCryst Pharmaceuticals reported revenue of $145.5M and eps of $0.00 for Q1 2025.
Did BioCryst Pharmaceuticals beat estimates in Q1 2025?
Revenue missed the consensus estimate of $149.7M by $4.2M. EPS beat the consensus estimate of $-0.07 by $0.07.
How did BioCryst Pharmaceuticals's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 56.9% from $92.8M a year earlier.
Where can I find BioCryst Pharmaceuticals's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001171843-25-002739) and the 10-Q periodic report (0001628280-25-022658) directly on SEC EDGAR. The filing index links above go to sec.gov.